Phase 2 Stroke Trial, Recruiting NCT05630586 Sponsor: Aarhus University Hospital Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT05630586
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have given their consent (or had consent given on their behalf) to participate.
  • People who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) with noticeable neurological effects, such as problems with speech, movement, thinking, eye movement, vision, awareness of one side of the body, or coordination.
  • People whose stroke symptoms started, or who were last seen to be well, less than 4.5 hours before being entered into the trial.
  • People who had little to no disability in day-to-day life before their stroke (confirm with trial site for how this is measured).

Who may not be able to join:

  • People who have a known diagnosis of diabetes, or whose blood sugar level at admission is above a certain level (above 11.1 mmol/L).
  • People with a body mass index (a measure of body weight relative to height) below 22.
  • People with a history of pancreatitis (inflammation of the pancreas) or a type of thyroid cancer called medullary thyroid carcinoma.
  • People who have, or are predisposed to, a genetic condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which affects hormone-producing glands.
  • People who are not expected to live for more than 12 months, or who have a serious degenerative brain or nervous system condition.
  • People who are pregnant, planning to become pregnant within the next 12 months, or currently breastfeeding.
  • People with significantly reduced kidney function, as measured by a specific kidney filtration test (confirm with trial site for exact threshold).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Claus Z Simonsen, Professor, Aarhus University Hospital

Phone: 004551430175

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Aarhus University Hospital
Registry
ClinicalTrials.gov
Start date
12 April 2023
Est. completion
1 September 2025

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Modified Ranking Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov